We are excited to announce the installation of a z-Movi® Cell Avidity Analyzer at Charité – Universitätsmedizin Berlin!
The z-Movi will be used by the research team led by Dr. Matthias Leisegang, Juniorprofessor at the Institute of Immunology. This unique instrument measures the interaction strength between target tumor cells and effector T cells, and will play a crucial role in analyzing the efficacy of TCR immunotherapies. The team is particularly interested in using the z-Movi to study the cellular avidity of new TCRs for clinical applications, primarily targeting tumor neoantigens. The z-Movi will enable them to unveil binding events between T cells and target cells, improving their understanding of intercellular interactions and accelerate adoptive T cell therapy development.
“The z-Movi instrument allows us to get information of how strong the binding between two partners is. Acoustic force measurements allow for the first time to make an exact determination of the force that is necessary to separate two cell partners, which introduces a new parameter that characterizes the T cells. It is unique and I believe there is no other instrument that can do this type of measurement.” — Dr. Matthias Leisegang, Charité – Universitätsmedizin Berlin
To learn more how cell avidity measurement enables the team to identify effective TCR T cell therapy, check out our interview with Dr. Leisegang here.
We wish Dr. Leisegang and his team all the best with their upcoming experiments, and we are looking forward to see the results!
Top banner image was licensed by photocosmos1 / Shutterstock.com.
